MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman

MLTX Investor with Losses Encourages to Contact Firm by Dec. 15 Deadline SAN FRANCISCO , Dec. 3, 2025 /PRNewswire/ -- Global plaintiffs' rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit against MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX) is December 15, 2025 . "In specialized biotech cases, the core legal question is often whether the company's claims about the study match the reality of the clin ...